TY - GEN
T1 - Outcomes following treatment discontinuation in CML: real-world experience from 3 regional UK centres
AU - Kwok, Marwan Cheng Kuang
AU - Shenouda, Amir
AU - Duncan, Nick
AU - Hasan, Yasmin
AU - Ewing, Joanne
AU - Raghavan, Manoj
AU - Wandroo, Farooq
PY - 2019/6
Y1 - 2019/6
N2 - Emerging evidence from clinical trials has demonstrated the feasibility of TKI discontinuation in CML. However, real-world data of treatment discontinuation has been limited, particularly where this is due to clinical considerations such as drug toxicities. To address the real-world outcomes of treatment discontinuation and factors influencing this, we retrospectively analysed all patients from 3 hospitals in Birmingham, UK who have discontinued CML treatment since 2010.
AB - Emerging evidence from clinical trials has demonstrated the feasibility of TKI discontinuation in CML. However, real-world data of treatment discontinuation has been limited, particularly where this is due to clinical considerations such as drug toxicities. To address the real-world outcomes of treatment discontinuation and factors influencing this, we retrospectively analysed all patients from 3 hospitals in Birmingham, UK who have discontinued CML treatment since 2010.
UR - http://dx.doi.org/10.1097/01.hs9.0000566280.83009.25
U2 - 10.1097/01.hs9.0000566280.83009.25
DO - 10.1097/01.hs9.0000566280.83009.25
M3 - Conference contribution
VL - 3
T3 - HemaSphere
SP - 884
BT - HemaSphere
ER -